BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodin SN, Rodin AS. Strand asymmetry of CpG transitions as indicator of G1 phase-dependent origin of multiple tumorigenic p53 mutations in stem cells. Proc Natl Acad Sci U S A 1998;95:11927-32. [PMID: 9751767 DOI: 10.1073/pnas.95.20.11927] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.2] [Reference Citation Analysis]
Number Citing Articles
1 Rodin SN, Rodin AS. On the origin of p53 G:C → T:A transversions in lung cancers. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis 2002;508:1-19. [DOI: 10.1016/s0027-5107(02)00106-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
2 Farid NR. P53 and other Cell Cycle Regulators. In: Farid NR, editor. Molecular Basis of Thyroid Cancer. Boston: Kluwer Academic Publishers; 2005. pp. 149-64. [DOI: 10.1007/1-4020-8107-3_8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
3 Forcelloni S, Giansanti A. Evolutionary Forces and Codon Bias in Different Flavors of Intrinsic Disorder in the Human Proteome. J Mol Evol 2020;88:164-78. [DOI: 10.1007/s00239-019-09921-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
4 Lamolle G, Marin M, Alvarez-Valin F. Silent mutations in the gene encoding the p53 protein are preferentially located in conserved amino acid positions and splicing enhancers. Mutat Res 2006;600:102-12. [PMID: 16650445 DOI: 10.1016/j.mrfmmm.2006.03.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
5 Belyavskaya VA, Vardosanidze VK, Smirnova OY, Karakin EI, Savkin IV, Gervas PA, Cherdyntseva NV, Voevoda MI. Genetic status of p53 in stomach cancer: Somatic mutations and polymorphism of codon 72. Bull Exp Biol Med 2006;141:243-6. [DOI: 10.1007/s10517-006-0139-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
6 Farid NR. P53 mutations in thyroid carcinoma: tidings from an old foe. J Endocrinol Invest. 2001;24:536-545. [PMID: 11508790 DOI: 10.1007/bf03343889] [Cited by in Crossref: 26] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
7 Dunn GP, Andronesi OC, Cahill DP. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma. Neurosurg Focus 2013;34:E2. [PMID: 23373447 DOI: 10.3171/2012.12.FOCUS12355] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
8 Malcikova J, Pavlova S, Kozubik KS, Pospisilova S. TP53 Mutation Analysis in Clinical Practice: Lessons From Chronic Lymphocytic Leukemia. Human Mutation 2014;35:663-71. [DOI: 10.1002/humu.22508] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
9 Da R, Wang M, Jiang H, Wang T, Wang W. BRAF AMP Frequently Co-occurs With IDH1/2, TP53, and ATRX Mutations in Adult Patients With Gliomas and Is Associated With Poorer Survival Than That of Patients Harboring BRAF V600E. Front Oncol 2020;10:531968. [PMID: 33489866 DOI: 10.3389/fonc.2020.531968] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 2012;26:756-784. [PMID: 22508724 DOI: 10.1101/gad.187922.112.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Zenz T, Vollmer D, Trbusek M, Smardova J, Benner A, Soussi T, Helfrich H, Heuberger M, Hoth P, Fuge M, Denzel T, Häbe S, Malcikova J, Kuglik P, Truong S, Patten N, Wu L, Oscier D, Ibbotson R, Gardiner A, Tracy I, Lin K, Pettitt A, Pospisilova S, Mayer J, Hallek M, Döhner H, Stilgenbauer S; European Research Initiative on CLL (ERIC). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia 2010;24:2072-9. [PMID: 20861914 DOI: 10.1038/leu.2010.208] [Cited by in Crossref: 95] [Cited by in F6Publishing: 89] [Article Influence: 7.9] [Reference Citation Analysis]
12 Trbusek M, Malcikova J. TP53 aberrations in chronic lymphocytic leukemia. Adv Exp Med Biol 2013;792:109-31. [PMID: 24014294 DOI: 10.1007/978-1-4614-8051-8_5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
13 Rodin SN, Rodin AS. Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci U S A 2000;97:12244-9. [PMID: 11035769 DOI: 10.1073/pnas.180320897] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 2.7] [Reference Citation Analysis]
14 Bergstein I. A non-Darwinian role for mutagenesis in stem cell-derived cancers. Mol Carcinog 2003;36:1-5. [PMID: 12503073 DOI: 10.1002/mc.10092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011;29:4482-4490. [PMID: 22025148 DOI: 10.1200/jco.2010.33.8715] [Cited by in Crossref: 310] [Cited by in F6Publishing: 187] [Article Influence: 28.2] [Reference Citation Analysis]
16 Dunn GP, Rinne ML, Wykosky J, Genovese G, Quayle SN, Dunn IF, Agarwalla PK, Chheda MG, Campos B, Wang A, Brennan C, Ligon KL, Furnari F, Cavenee WK, Depinho RA, Chin L, Hahn WC. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012;26:756-84. [PMID: 22508724 DOI: 10.1101/gad.187922.112] [Cited by in Crossref: 345] [Cited by in F6Publishing: 333] [Article Influence: 34.5] [Reference Citation Analysis]
17 Kouidou S, Malousi A, Kyventidis A, Fragou A, Maglaveras N. G:C > A:T mutations and potential epigenetic regulation of p53 in breast cancer. Breast Cancer Res Treat 2007;106:351-60. [PMID: 17505880 DOI: 10.1007/s10549-007-9514-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
18 Wang W, Wang M, Jiang H, Wang T, Da R. BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage. BMC Neurol 2021;21:195. [PMID: 33980169 DOI: 10.1186/s12883-021-02224-6] [Reference Citation Analysis]
19 Zhao Y, Epstein RJ. Conserved nonsense-prone CpG sites in apoptosis-regulatory genes: conditional stop signs on the road to cell death. Evol Bioinform Online 2013;9:275-83. [PMID: 23908585 DOI: 10.4137/EBO.S11759] [Reference Citation Analysis]
20 Strauss BS. Role in tumorigenesis of silent mutations in the TP53 gene. Mutat Res 2000;457:93-104. [PMID: 11106801 DOI: 10.1016/s0027-5107(00)00135-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
21 Heinmöller E, Dietmaier W, Zirngibl H, Heinmöller P, Scaringe W, Jauch KW, Hofstädter F, Rüschoff J. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol 2000;157:83-92. [PMID: 10880379 DOI: 10.1016/S0002-9440(10)64520-8] [Cited by in Crossref: 75] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
22 Gorlov IP, Gorlova OY, Frazier ML, Amos CI. Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs). Mutat Res 2004;554:175-83. [PMID: 15450416 DOI: 10.1016/j.mrfmmm.2004.04.014] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
23 Shahedian B, Shi Y, Zou M, Farid NR. Thyroid carcinoma is characterized by genomic instability: evidence from p53 mutations. Mol Genet Metab 2001;72:155-63. [PMID: 11161841 DOI: 10.1006/mgme.2000.3114] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
24 Mohamadkhani A, Naderi E, Sharafkhah M, Fazli HR, Moradzadeh M, Pourshams A. Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. J Oncol 2013;2013:738915. [PMID: 24489544 DOI: 10.1155/2013/738915] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
25 Pfeifer GP, Tang M, Denissenko MF. Mutation Hotspots and DNA Methylation. In: Jones PA, Vogt PK, editors. DNA Methylation and Cancer. Berlin: Springer Berlin Heidelberg; 2000. pp. 1-19. [DOI: 10.1007/978-3-642-59696-4_1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 25] [Article Influence: 0.6] [Reference Citation Analysis]
26 Rodin SN, Rodin AS, Juhasz A, Holmquist GP. Cancerous hyper-mutagenesis in p53 genes is possibly associated with transcriptional bypass of DNA lesions. Mutat Res 2002;510:153-68. [PMID: 12459451 DOI: 10.1016/s0027-5107(02)00260-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
27 Hashimoto K, Rogozin IB, Panchenko AR. Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases. Hum Mutat 2012;33:1566-75. [PMID: 22753356 DOI: 10.1002/humu.22145] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
28 Xu F, Dong C, Xie C, Ren J. Ultrahighly sensitive homogeneous detection of DNA and microRNA by using single-silver-nanoparticle counting. Chemistry 2010;16:1010-6. [PMID: 19938021 DOI: 10.1002/chem.200902555] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]